A

Alkeus Pharmaceuticals

HealthUnited States

Alkeus Pharmaceuticals is a biotechnology startup focused on developing a treatment for Stargardt disease, a genetic condition that leads to progressive vision loss. The company is notable for its innovative drug, gildeuretinol, which has shown promise in clinical trials and is now being acquired by Tarsus Pharmaceuticals for up to $800 million.

$800MVisit website ↗

🏆 Featured in Datapile’s Q3 2026 USA Funding Report

Read the Q3 2026 USA report →
Add this badge to your site
Featured in Datapile’s Q3 2026 USA Funding Report
<a href="https://datapile.co/reports/q3-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q3 2026 USA Funding Report</a>

Funding history

  1. $800M2026-08-06
    Source: news.google.com ↗

Founder

L
Leonide Saad
Founder

Investors in Alkeus Pharmaceuticals

Backers from this company's tracked funding rounds.

  • Bain Capital Life Sciences
  • TCGX

More Health companies

Recently funded startups in the same category.

Related on Datapile